TTC39A Antibody

What types of TTC39A antibodies are currently available for research?

Currently, researchers have access to polyclonal antibodies against TTC39A from several manufacturers. These antibodies have been validated for various applications including Western blotting (WB), immunohistochemistry (IHC), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA) . Most commercially available TTC39A antibodies demonstrate species specificity for human, mouse, and rat samples . Polyclonal antibodies are particularly useful for detecting low-abundance proteins and can recognize multiple epitopes of the target protein, potentially increasing detection sensitivity in various experimental contexts .

What is the molecular weight of TTC39A and how does this impact antibody selection?

TTC39A has a calculated molecular weight of approximately 70 kDa (613 amino acids), with observed molecular weights on SDS-PAGE gels ranging from 65-70 kDa . This slight variation may reflect post-translational modifications or different isoforms of the protein. When selecting an antibody for Western blot applications, researchers should confirm that the antibody recognizes proteins within this molecular weight range and validate specificity using appropriate positive controls such as mouse liver tissue or MCF-7 cells, which have been documented to express TTC39A .

What are the optimal protocols for using TTC39A antibodies in immunohistochemistry?

For immunohistochemistry applications using TTC39A antibodies, the following methodological considerations are recommended:

• Antigen retrieval: Use TE buffer at pH 9.0 as the primary method, though citrate buffer at pH 6.0 may serve as an alternative .

• Antibody dilution: Optimal dilutions range from 1:20 to 1:200 depending on the specific antibody and tissue type . For human breast cancer tissue and human testis tissue, which serve as positive controls, a dilution of 1:50 has proven effective .

• Incubation conditions: Room temperature incubation is typically sufficient, though specific time requirements may vary based on the manufacturer's recommendations.

• Detection system: Standard avidin-biotin complex (ABC) or polymer-based detection systems are compatible with most TTC39A antibodies.

• Controls: Include positive controls (breast cancer tissue or testis tissue) and negative controls (primary antibody omission) to validate staining specificity .

How should researchers optimize Western blot protocols for TTC39A detection?

For optimal Western blot detection of TTC39A protein:

• Sample preparation: Total protein extraction using RIPA buffer supplemented with protease inhibitors is recommended.

• Protein loading: Load 20-50 μg of total protein per lane for adequate detection.

• Gel percentage: Use 8-10% SDS-PAGE gels to optimally resolve proteins in the 65-70 kDa range.

• Transfer conditions: Semi-dry or wet transfer at 100V for 60-90 minutes is effective for proteins of this size.

• Blocking: 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Antibody dilution: Recommended dilutions range from 1:500 to 1:1000 for primary antibody incubation .

• Incubation: Overnight incubation at 4°C typically yields optimal results, though room temperature incubation for 1.5 hours has also proven effective .

• Positive controls: Mouse liver tissue and MCF-7 cells serve as reliable positive controls .

• Expected band: Look for specific bands in the 65-70 kDa range .

What methods are effective for studying TTC39A in immunofluorescence applications?

For immunofluorescence applications:

• Cell fixation: 4% paraformaldehyde for 15 minutes followed by permeabilization with 0.1% Triton X-100.

• Blocking: 1-3% BSA in PBS for 30-60 minutes.

• Antibody dilution: Recommended dilutions for primary antibody range from 1:10 to 1:100 .

• Secondary antibody: Rhodamine-labeled anti-rabbit IgG has been successfully used .

• Nuclear counterstain: DAPI is commonly used for nuclear visualization .

• Cell types: HepG2 and HeLa cells have been validated as appropriate cell models for TTC39A immunofluorescence studies .

• Controls: Include cells with known TTC39A expression levels and secondary-only controls to confirm specificity.

What is the relationship between TTC39A and the immune microenvironment in cancer, and how can this be investigated?

Recent research has uncovered important associations between TTC39A expression and immune cell infiltration in various cancer types . To investigate this relationship:

• Immune cell profiling: Use computational methods to estimate immune cell infiltration levels from RNA-seq data, or employ multiplex immunohistochemistry or flow cytometry for direct quantification.

• Correlation analysis: Perform correlation analyses between TTC39A expression and various immune cell populations to identify significant associations.

• Survival impact assessment: Conduct stratified analyses to evaluate how the combination of TTC39A expression and immune cell infiltration levels affects patient survival.

• Functional validation: Design in vitro co-culture experiments with cancer cells expressing varying levels of TTC39A and relevant immune cell populations to assess functional interactions.

• Pathway analysis: Employ Gene Set Enrichment Analysis (GSEA) to identify immune-related pathways associated with TTC39A expression .

These methodological approaches have revealed that TTC39A expression is related to the infiltration of specific immune cell types in LGG, LIHC, and SKCM, and that the combination of TTC39A expression and immune cell infiltration levels can significantly impact patient survival .

What are the functional roles of TTC39A-related non-coding RNAs and how can researchers study their interactions?

TTC39A antisense RNA 1 (TTC39A-AS1), a long non-coding RNA, has been identified as a regulator in breast cancer with significant implications for cancer progression . To study the functional relationships between TTC39A and its associated non-coding RNAs:

• Expression correlation: Assess the correlation between TTC39A and TTC39A-AS1 expression in cancer tissues using qRT-PCR.

• Knockdown/overexpression experiments: Perform siRNA-mediated knockdown or vector-based overexpression of TTC39A-AS1 and evaluate the effects on TTC39A expression and cellular functions.

• Competing endogenous RNA (ceRNA) analysis: Investigate the potential ceRNA function of TTC39A-AS1 by:

  • Identifying potential microRNA binding sites using bioinformatics tools

  • Performing luciferase reporter assays to confirm direct binding

  • Conducting RNA immunoprecipitation (RIP) to validate RNA-RNA interactions

• Functional assays: Evaluate the impact of TTC39A-AS1 manipulation on cell proliferation, apoptosis, migration, and invasion using:

  • Cell Counting Kit 8 assay for proliferation

  • Flow cytometric analysis for apoptosis

  • Transwell assays for migration and invasion

Research has shown that TTC39A-AS1 functions as a competing endogenous RNA by sponging miR-483-3p, thereby indirectly increasing metastasis-associated gene 2 (MTA2) expression in breast cancer . This TTC39A-AS1/miR-483-3p/MTA2 pathway represents a critical regulatory mechanism in breast cancer tumorigenesis .

What are common technical challenges when working with TTC39A antibodies and how can they be addressed?

Researchers may encounter several technical challenges when working with TTC39A antibodies:

• Background signal in Western blots:

  • Increase blocking time or BSA concentration in blocking buffer

  • Optimize antibody dilution (try 1:800-1:1000)

  • Include 0.1% Tween-20 in washing steps

  • Consider using a different secondary antibody

• Weak or absent signal:

  • Verify TTC39A expression in your sample using positive controls (mouse liver tissue, MCF-7 cells)

  • Increase protein loading amount

  • Extend primary antibody incubation time

  • Use enhanced chemiluminescence detection with longer exposure

• Non-specific bands:

  • Increase stringency of washing steps

  • Optimize primary antibody concentration

  • Confirm molecular weight (expected: 65-70 kDa)

  • Use freshly prepared samples to minimize protein degradation

• Variability in immunohistochemistry results:

  • Standardize antigen retrieval methods (preferably TE buffer pH 9.0)

  • Optimize antibody dilution (1:20-1:200 range)

  • Control incubation times and temperatures precisely

  • Use automated staining platforms when available for consistency

How can researchers validate the specificity of TTC39A antibodies in their experimental systems?

Rigorous validation of TTC39A antibodies is essential for generating reliable research data. Recommended validation approaches include:

• Positive and negative controls:

  • Use tissues/cells with known TTC39A expression (mouse liver, MCF-7 cells, breast cancer tissue)

  • Include samples with TTC39A knockdown or knockout as negative controls

• Peptide competition assay:

  • Pre-incubate the antibody with excess immunizing peptide

  • Perform parallel experiments with blocked and unblocked antibody

  • Specific signals should be diminished or eliminated in the presence of competing peptide

• Molecular weight verification:

  • Confirm that detected bands align with the expected molecular weight (65-70 kDa)

• Cross-validation with multiple antibodies:

  • Test multiple antibodies targeting different epitopes of TTC39A

  • Consistent results across different antibodies support specificity

• Orthogonal methods:

  • Validate protein expression using independent techniques (e.g., mass spectrometry)

  • Correlate protein detection with mRNA expression data

How is TTC39A involved in biological processes beyond cancer, and what approaches can be used to investigate these functions?

While TTC39A has been primarily studied in cancer contexts, functional enrichment and gene set enrichment analyses suggest involvement in multiple biological processes . To investigate these broader functions:

• Protein-protein interaction mapping:

  • Perform co-immunoprecipitation followed by mass spectrometry

  • Use proximity labeling techniques (BioID, APEX) to identify interaction partners

  • Analyze yeast two-hybrid screening results to identify direct interactors

• Subcellular localization studies:

  • Conduct fractionation experiments followed by Western blotting

  • Perform immunofluorescence with organelle-specific markers

  • Generate fluorescently tagged TTC39A for live-cell imaging

• Pathway analysis:

  • Perform RNA-seq after TTC39A knockdown/overexpression

  • Use GSEA to identify enriched pathways

  • Conduct targeted validation of key pathway components

• CRISPR-based functional genomics:

  • Generate TTC39A knockout cell lines using CRISPR-Cas9

  • Perform phenotypic screening to identify altered cellular functions

  • Use CRISPRi/CRISPRa for reversible modulation of TTC39A expression

These approaches can help elucidate the broader biological functions of TTC39A beyond its emerging roles in cancer biology.

What are the latest developments in using artificial intelligence to predict antibody-antigen interactions for TTC39A research?

Recent advances in AI-based tools offer promising approaches for optimizing antibody-based research on TTC39A:

• Deep learning models for antibody-antigen interaction prediction:

  • New tools like AF2Complex use deep learning to predict antibody binding to specific antigens with high accuracy (up to 90% in test cases)

  • These models can help researchers select the most effective antibodies for specific applications

• Sequence-based prediction approaches:

  • Analysis of evolutionary relationships and patterns in antibody sequences improves prediction accuracy

  • Researchers can leverage these tools to identify antibodies likely to target specific TTC39A epitopes

• 3D structure prediction:

  • AI models like AlphaFold2 can predict protein complex structures, including antibody-antigen complexes

  • These predictions help visualize potential binding sites and optimize antibody selection

• Multi-epitope targeting strategies:

  • AI tools can identify antibodies targeting distinct epitopes on the same protein

  • This enables more comprehensive protein detection and functional analysis

Researchers investigating TTC39A can leverage these AI-based approaches to optimize antibody selection, improving experimental outcomes and accelerating research progress.